Last updated on January 2020

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

Brief description of study

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Clinical Study Identifier: NCT03732677

Find a site near you

Start Over

Research Site

Prahran, Australia
  Connect »

Research Site

Box Hill, Australia
  Connect »